Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polyinosinic acid-polycytidylic acid dominated adjuvant

A polyribocytidylic acid and polynucleotide technology, which is used in medical preparations containing active ingredients, antibody medical ingredients, pharmaceutical formulas, etc., and can solve problems such as adverse side effects and inability to provide efficacy/safety status.

Inactive Publication Date: 2013-11-27
YISHENG BIOPHARMA SINGAPORE
View PDF22 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The inventors of this case found that Av-PICKCa does not provide the best efficacy / safety status when used as an adjuvant, and PICKCa does cause unacceptable adverse side effects in some cases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polyinosinic acid-polycytidylic acid dominated adjuvant
  • Polyinosinic acid-polycytidylic acid dominated adjuvant
  • Polyinosinic acid-polycytidylic acid dominated adjuvant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0209] Embodiment 1. Measure the molecular weight of PIKA and AV-PICKCA

[0210] This example illustrates the assay format for PIKA adjuvant and compares it with Av-PICKCa.

[0211] Agarose gel electrophoresis is well known to those skilled in the art, so this description only describes the features of the invention. The agarose gel used in the present invention has a concentration of 1.5% agarose. Molecular markers are 100bp DNA ladders from 100bp to 1000bp, corresponding to 6.6x10 4 up to 6.6x10 5 Dalton's molecular weight range. The concentration of the 4ul loaded sample is 1mg / ml. figure 1 Shows a representative graph of the results of an agarose gel sample obtained following the teachings of this paragraph. Five (5) different batches were tested showing a broad range of their molecular weight distributions. Their upper molecular weight limit is 2.3x10 in Av-PICKCa 5 Dalton to PIKA is 5.28x10 5 Dalton range.

Embodiment 2

[0212] Example 2. Comparison of Immunological Effectiveness of PIKA and AV-PICKCA

[0213] This example shows the difference in potency strength between Av-PICKCa with a maximum molecular weight of 230,000 Daltons and a PIKA sample with a maximum molecular weight of 528,000 Daltons.

[0214] Three batches of PIKA adjuvant with different molecular weights, and one batch with a molecular weight corresponding to the molecular weight of Av-PIKA, were combined with hamster kidney cell inactivated purified rabies antigen (HKC-IPRA). Subsequently, the resulting composition was subjected to NIH potency testing.

[0215] The NIH Efficacy Trial is a rigorous and experimentally intensive comparative study comparing a test rabies vaccine with a standard rabies vaccine. Vaccinated mice were infected with a live rabies virus strain and their survival was measured. Different dilutions of rabies vaccine were administered to different groups of mice. The potency of the experimental vaccine ...

Embodiment 3

[0219] Interferon Production Comparison Between Example 3.PIKA and Av-PICKCA

[0220] This example shows the difference in the ability to induce interferon production between Av-PICKCa samples with an upper molecular weight limit of 230,000 Daltons and PIKA samples with an upper molecular weight limit of 1,200,000 Daltons.

[0221] The second batch has an upper molecular weight limit of 1.2x10 6 Dalton and 4.6x10 5 Dalton's PIKA, and a batch with an upper molecular weight of 2.3x10 5 Dalton's Av-PICKCa for comparison.

[0222] The PIKA and Av-PICKCa compositions were combined with hamster kidney cell inactivated purified rabies antigen (HKC-IPRA). These compositions were injected subcutaneously into mice. Two hours later, the level of interferon in the serum of each mouse was measured. General procedures for measuring interferon are known to those skilled in the art. Briefly, about 30,000 L929 cells were seeded at 0.15ml / well in a 96-well culture plate. Three days later...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Molecular weightaaaaaaaaaa
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides a polyinosinic acid-polycytidylic acid dominated adjuvant. The invention provides an oligonucleotide adjuvant composition and an immunoreaction initiated application method thereof. The invention also provides an immunogen composition containing the oligonucleotide adjuvant composition and an antigen, for example, the two components are in a vaccine. The adjuvant composition disclosed by the invention has specific physical properties such as molecular weight, concentration and pH, and the properties can meet a required effective and safe adjuvant capable of inducing and strengthening immunoreaction and changing the type of immunoreaction. The invention further relates to application methods of the adjuvant compositions, and particularly relates to a method for inducing the immunoreaction for antigen compositions.

Description

[0001] This application is a divisional application of the Chinese patent application with the application number 200580015097.2, the application date is June 8, 2005, and the invention title is "adjuvant mainly based on polyinosinic acid-polycytidylic acid". technical field [0002] The present invention relates generally to adjuvant compositions and methods of using these adjuvant compositions to promote an immune response, and in particular to compositions, vaccines and methods for promoting the immunogenicity of antigens. It relates more particularly to polynucleotide adjuvant compositions, vaccines containing the polynucleotide adjuvant compositions, and methods of using the polynucleotide adjuvant compositions and vaccines to promote an immune response in a host. Background technique [0003] Description of related technologies [0004] The immune system has the ability to produce specific and nonspecific immunity. In general, B and T lymphocytes have specific recepto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/39
Inventor 林海祥
Owner YISHENG BIOPHARMA SINGAPORE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com